Emergent BioSolutions Inc. 2014 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Emergent BioSolutions Inc.
Reporting Period: Fiscal year ended December 31, 2014
Business Model: A global specialty biopharmaceutical company operating in two segments: Biodefense (countermeasures for CBRNE threats, primarily sold to the U.S. government) and Biosciences (therapeutics and vaccines for hematology/oncology, infectious disease, and autoimmunity).
Key Developments: In February 2014, the company acquired Cangene Corporation for approximately $222 million, significantly expanding its Biosciences portfolio and manufacturing capabilities. In December 2014, it acquired the EV-035 series of antibiotic molecules from Evolva SA.
Key Financial Metrics (Year Ended Dec 31, 2014)
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Total Revenues | $450.1 million | $312.7 million | +44% |
| Net Income | $36.7 million | $31.1 million | +18% |
| Diluted EPS | $0.88 | $0.85 | +4% |
| Operating Cash Flow | $112.3 million | $97.0 million | +16% |
| Cash & Equivalents | $280.5 million | $179.3 million | +56% |
| Total Debt | $251.0 million | $62.0 million | +305% |
| Working Capital | $339.2 million | $216.5 million | +57% |
Note: Revenue growth was driven by the Cangene acquisition and increased government contract funding. Debt increased due to the issuance of $250 million in 2.875% Convertible Senior Notes in January 2014.
Material Changes vs. Prior Period
- Revenue Composition: Product sales increased 20% to $308.3 million, driven by the inclusion of Cangene products (WinRho SDF, HepaGam B, VARIZIG, BAT, Anthrasil, VIGIV) and RSDL. Contracts, grants, and collaborations revenue more than doubled to $110.8 million, largely due to development funding for acquired products and a $15.6 million upfront payment from a MorphoSys collaboration.
- Expenses: Operating expenses rose significantly. Cost of product sales increased 91% to $118.4 million due to Cangene integration. R&D expenses increased 26% to $150.8 million, reflecting higher development costs for new product candidates. SG&A increased 40% to $122.8 million due to acquisition-related professional fees and integration costs.
- Segment Performance: The Biodefense segment generated net income of $97.0 million, while the Biosciences segment incurred a net loss of $51.3 million, consistent with its historical profile as a growth investment.
Guidance, Outlook, Risks, and Unusual Items
Guidance Status: The company has suspended its 2015 financial guidance.
Unusual Item / Critical Risk: In late January 2015 (subsequent to year-end), the company discovered foreign particles in two manufactured lots of its primary product, BioThrax.
- Action: Two lots were rejected, and 13 additional lots were quarantined pending investigation.
- Impact: No BioThrax deliveries are expected in Q1 2015. The company estimates a potential revenue impact of $0 to $65 million for 2015 and an inventory loss of $2 million to $15 million.
- Investigation: The company is investigating its operations and those of suppliers/contract manufacturers, aiming to complete the investigation within 60 days.
Other Risks:
- Government Dependence: The U.S. government remains the primary customer for Biodefense products (74.3% of total revenue in 2014). Funding is subject to Congressional appropriations and sequestration.
- Regulatory: The FDA issued a Complete Response Letter for the IXINITY (hemophilia B) NDA in July 2014, requiring additional data analysis.
- Debt Covenants: The company must maintain specific leverage and liquidity ratios under its credit facility.
Investor Verification Checklist
- BioThrax Investigation Status: Monitor updates on the foreign particle investigation, specifically the disposition of the 13 quarantined lots and the timeline for resuming deliveries.
- 2015 Revenue Outlook: Verify if the $0-$65 million revenue impact estimate holds or if the scope of the issue expands.
- Cangene Integration: Assess the realization of cost synergies and the profitability trajectory of the Biosciences segment post-acquisition.
- IXINITY Regulatory Path: Track the resubmission timeline and FDA response for the hemophilia B product candidate.
- Debt Servicing: Confirm compliance with debt covenants given the potential near-term revenue disruption from BioThrax.